Lazertinib Mesylate Hydrate
Lazertinib works by blocking the activity of abnormal EGFR proteins that signal cancer cells to divide. This keeps cancer cells from growing and may kill them. Lazertinib can reach cancer cells in the brain, enabling it to treat cancers that have spread there. It is a type of targeted therapy drug called an EGFR tyrosine kinase inhibitor.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Lazertinib mesylate hydrate is approved to treat adults with:
- non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery and has an abnormal EGFR gene. It is used with amivantamab as the first treatment.
More About Lazertinib Mesylate Hydrate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Lazertinib Mesylate Hydrate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Lazertinib Mesylate Hydrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.